Provided By GlobeNewswire
Last update: Oct 30, 2025
Châtillon, France, October 30, 2025
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company’s shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company’s Board comprises ten directors.
Read more at globenewswire.comNASDAQ:DBVT (12/12/2025, 8:24:12 PM)
18.37
-1.05 (-5.43%)
Find more stocks in the Stock Screener


